Nivolumab: tested on its own
215 studies: no other medicine in its arm. Page 1 of 3. Open to participants first (28), then studies with results posted, then the rest; newest registration first within each.
- An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCCNot yet recruitingNCT07902258Phase 2Report a problem
- Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)RecruitingNCT07653503Phase 1Report a problem
- Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal CancerRecruitingNCT07645118Phase 2Report a problem
- Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO TrialNot yet recruitingNCT07576725Phase 2Report a problem
- Evaluation of the Efficacy and Safety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced Oral Squamous Cell CarcinomaNot yet recruitingNCT07514767Phase 2Report a problem
- PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaRecruitingNCT07209059Phase 2Report a problem
- Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell CarcinomaRecruitingNCT07152678Phase 2Report a problem
- Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of NivolumabRecruitingNCT07100704Phase 2Report a problem
- ONO-4538 Study in Patients With Richter's TransformationRecruitingNCT06936943Phase 2Report a problem
- Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab TreatmentEnrolling by invitationNCT06931613Phase 2Report a problem
- Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell LymphomaEnrolling by invitationNCT06871007Phase 1/2Report a problem
- Study to ONO-4538 in Patients With Rhabdoid TumorRecruitingNCT06622941Phase 2Report a problem
- Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant LesionsRecruitingNCT06561087Phase 2Report a problem
- A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)RecruitingNCT06519682Not applicableReport a problem
- Repositioning Immunotherapy in VetArans With Lung CancerRecruitingNCT06275360Phase 2Report a problem
- Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramRecruitingNCT06265285Phase 2Report a problem
- Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable ResponseRecruitingNCT06116461Phase 4Report a problem
- Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell CarcinomaRecruitingNCT05964101Phase 2Report a problem
- Effect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical TrialNot yet recruitingNCT05887830Phase 1/2Report a problem
- Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)RecruitingNCT05795244Phase 2Report a problem
- Safe Stop Ipilimumab-nivolumab (IPI-NIVO) TrialRecruitingNCT05652673Not applicableReport a problem
- Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)RecruitingNCT05112549Phase 1Report a problem
- Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based TreatmentRecruitingNCT04875611Phase 2Report a problem
- The IMmunotherapy Pleural 5-ALA PDTRecruitingNCT04400539Phase 2Report a problem
- Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb PerfusionRecruitingNCT03685890Phase 1/2Report a problem
- Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With SarcomaRecruitingNCT03465592Phase 1/2Report a problem
- Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasRecruitingNCT03258567Phase 2Report a problem
- Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic AdenocarcinomaRecruitingNCT03080974Phase 2Report a problem
- Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)CompletedNCT04439214Phase 2Results postedReport a problem
- Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesCompletedNCT04205409Phase 2Results postedReport a problem
- Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaActive, not recruitingNCT04099251Phase 3Results postedReport a problem
- Nivolumab in Biochemically Recurrent dMMR Prostate CancerCompletedNCT04019964Phase 2Results postedReport a problem
- A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal CancerCompletedNCT03981146Phase 2Results postedReport a problem
- Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator PhenotypeActive, not recruitingNCT03718767Phase 2Results postedReport a problem
- Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx CancerCompletedNCT03715946Phase 2Results postedReport a problem
- Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous LeukoplakiaCompletedNCT03692325Phase 2Results postedReport a problem
- Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate CancerActive, not recruitingNCT03637543Phase 2Results postedReport a problem
- Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)TerminatedNCT03634800Phase 2Results postedReport a problem
- Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial ColectomyTerminatedNCT03631641Phase 2Results postedReport a problem
- Nivolumab for Recurrent or Progressive IDH Mutant GliomasCompletedNCT03557359Phase 2Results postedReport a problem
- Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell CancerCompletedNCT03521570Phase 2Results postedReport a problem
- Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERSTerminatedNCT03495713Phase 2Results postedReport a problem
- Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)CompletedNCT03453164Phase 1/2Results postedReport a problem
- Study of Nivolumab for Advanced Cancers in IndiaCompletedNCT03444766Phase 4Results postedReport a problem
- Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression RiskCompletedNCT03436862Phase 2Results postedReport a problem
- Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for ChemoCompletedNCT03421652Phase 2Results postedReport a problem
- Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by SurgeryCompletedNCT03405155Phase 2Results postedReport a problem
- METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatinCompletedNCT03388190Phase 2Results postedReport a problem
- SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung EffectsCompletedNCT03383302Phase 1/2Results postedReport a problem
- Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive TherapyCompletedNCT03355560Phase 2Results postedReport a problem
- Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former SmokersActive, not recruitingNCT03347838Phase 2Results postedReport a problem
- Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT03325816Phase 1/2Results postedReport a problem
- A Study of Nivolumab in Selected Uterine Cancer PatientsCompletedNCT03241745Phase 2Results postedReport a problem
- A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in AsiaCompletedNCT03195491Phase 3Results postedReport a problem
- Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS CancersTerminatedNCT03173950Phase 2Results postedReport a problem
- Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT03090737Phase 2Results postedReport a problem
- Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell LymphomaTerminatedNCT03075553Phase 2Results postedReport a problem
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing NephrectomyActive, not recruitingNCT03055013Phase 3Results postedReport a problem
- Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity CancerCompletedNCT03021993Phase 2Results postedReport a problem
- Pilot Study of Nivolumab in Pediatric Patients With Hypermutant CancersTerminatedNCT02992964Phase 1/2Results postedReport a problem
- A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.CompletedNCT02960854Phase 1Results postedReport a problem
- Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation ExposureTerminatedNCT02864316Phase 2Results postedReport a problem
- A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)CompletedNCT02857426Phase 2Results postedReport a problem
- Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver CancerCompletedNCT02837029Phase 1Results postedReport a problem
- An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have SpreadCompletedNCT02832167Phase 2Results postedReport a problem
- Study of Nivolumab in Patients With Advanced Refractory Biliary Tract CancersCompletedNCT02829918Phase 2Results postedReport a problem
- Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell CarcinomaTerminatedNCT02781506Phase 2Results postedReport a problem
- An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction CancerCompletedNCT02743494Phase 3Results postedReport a problem
- Nivolumab in Treating Patients With Metastatic Adrenocortical CancerTerminatedNCT02720484Phase 2Results postedReport a problem
- A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 WeeksCompletedNCT02713867Phase 3Results postedReport a problem
- An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the CancerCompletedNCT02632409Phase 3Results postedReport a problem
- Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/LymphomaCompletedNCT02631746Phase 2Results postedReport a problem
- An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)CompletedNCT02617589Phase 3Results postedReport a problem
- Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung CancerCompletedNCT02613507Phase 3Results postedReport a problem
- An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell CarcinomaCompletedNCT02596035Phase 4Results postedReport a problem
- A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid TumorsCompletedNCT02593786Phase 1/2Results postedReport a problem
- An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaCompletedNCT02576509Phase 3Results postedReport a problem
- Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal CancerCompletedNCT02569242Phase 3Results postedReport a problem
- Nivolumab in AML in Remission at High Risk for RelapseCompletedNCT02532231Phase 2Results postedReport a problem
- Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerCompletedNCT02481830Phase 3Results postedReport a problem
- NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung CarcinomaCompletedNCT02434081Phase 2Results postedReport a problem
- Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera MyelofibrosisTerminatedNCT02421354Phase 2Results postedReport a problem
- An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLCCompletedNCT02409368Phase 2Results postedReport a problem
- Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV MelanomaCompletedNCT02388906Phase 3Results postedReport a problem
- A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder CancerCompletedNCT02387996Phase 2Results postedReport a problem
- Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal CancerCompletedNCT02339558Phase 2Results postedReport a problem
- Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN TrialActive, not recruitingNCT02275533Phase 2Results postedReport a problem
- ONO-4538 Phase I Study in Patients With Solid TumorCompletedNCT02261285Phase 1Results postedReport a problem
- Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical CancerActive, not recruitingNCT02257528Phase 2Results postedReport a problem
- ONO-4538 Study in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT02175017Phase 2Results postedReport a problem
- A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)CompletedNCT02156804Phase 2Results postedReport a problem
- Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)CompletedNCT02105636Phase 3Results postedReport a problem
- A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy RegimenCompletedNCT02066636Phase 3Results postedReport a problem
- Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)CompletedNCT02038946Phase 2Results postedReport a problem
- Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)CompletedNCT02038933Phase 2Results postedReport a problem
- Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic MelanomaCompletedNCT01721772Phase 3Results postedReport a problem
- Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic RegimensCompletedNCT01721759Phase 2Results postedReport a problem
- A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)CompletedNCT01721746Phase 3Results postedReport a problem
- Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLCCompletedNCT01673867Phase 3Results postedReport a problem
- Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)CompletedNCT01668784Phase 3Results postedReport a problem